Ten-year progression of obesity-related complications in a population with overweight and obesity in the UK: A retrospective open cohort study.

IF 5.4 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Jonathan Pearson-Stuttard, Sara Holloway, Kasper Sommer Matthiessen, Andrew Thompson, Silvia Capucci
{"title":"Ten-year progression of obesity-related complications in a population with overweight and obesity in the UK: A retrospective open cohort study.","authors":"Jonathan Pearson-Stuttard, Sara Holloway, Kasper Sommer Matthiessen, Andrew Thompson, Silvia Capucci","doi":"10.1111/dom.15836","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>To assess the prevalence of individual obesity-related complications (ORCs) and multimorbidity (≥ 1, ≥ 2 and ≥ 3 ORCs), and multimorbidity-associated healthcare costs, over 10 years.</p><p><strong>Methods: </strong>This retrospective open cohort study used Discover, a UK database of linked primary and secondary electronic health records. Adults were stratified by body mass index (BMI; overweight: 25-< 30 kg/m<sup>2</sup>; obesity class I: 30-< 35 kg/m<sup>2</sup>; obesity class II: 35-< 40 kg/m<sup>2</sup>; obesity class III: ≥ 40 kg/m<sup>2</sup>). Outcomes by year since baseline were assessed for serial cross sections across the study period (1 January 2004 to 31 December 2019; the index date was the date of first eligible BMI measurement).</p><p><strong>Results: </strong>Across 1 410 146 individuals (overweight: 1 008 101; obesity class I: 278 782; obesity class II: 80 621; obesity class III: 42 642), ORC prevalence was higher in successive BMI groups, and increases over time were generally greater for obesity relative to overweight. In those with ORC multimorbidity, both higher BMI and the presence of more ORCs were associated with higher annual per-person healthcare costs. Costs increased over time in those individuals with obesity and one or more ORC, as well as in those with obesity and two or more ORCs.</p><p><strong>Conclusions: </strong>Higher BMI was associated with higher baseline ORC prevalence and a greater increase in ORC prevalence over time, and with higher healthcare costs in those with multimorbidity. To reduce the burden of overweight and obesity on patients and healthcare systems, the presence, number and type of ORCs should be considered in developing effective, targeted prevention and management care pathways.</p>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":null,"pages":null},"PeriodicalIF":5.4000,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/dom.15836","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: To assess the prevalence of individual obesity-related complications (ORCs) and multimorbidity (≥ 1, ≥ 2 and ≥ 3 ORCs), and multimorbidity-associated healthcare costs, over 10 years.

Methods: This retrospective open cohort study used Discover, a UK database of linked primary and secondary electronic health records. Adults were stratified by body mass index (BMI; overweight: 25-< 30 kg/m2; obesity class I: 30-< 35 kg/m2; obesity class II: 35-< 40 kg/m2; obesity class III: ≥ 40 kg/m2). Outcomes by year since baseline were assessed for serial cross sections across the study period (1 January 2004 to 31 December 2019; the index date was the date of first eligible BMI measurement).

Results: Across 1 410 146 individuals (overweight: 1 008 101; obesity class I: 278 782; obesity class II: 80 621; obesity class III: 42 642), ORC prevalence was higher in successive BMI groups, and increases over time were generally greater for obesity relative to overweight. In those with ORC multimorbidity, both higher BMI and the presence of more ORCs were associated with higher annual per-person healthcare costs. Costs increased over time in those individuals with obesity and one or more ORC, as well as in those with obesity and two or more ORCs.

Conclusions: Higher BMI was associated with higher baseline ORC prevalence and a greater increase in ORC prevalence over time, and with higher healthcare costs in those with multimorbidity. To reduce the burden of overweight and obesity on patients and healthcare systems, the presence, number and type of ORCs should be considered in developing effective, targeted prevention and management care pathways.

英国超重和肥胖人群肥胖相关并发症的十年进展:一项回顾性开放队列研究。
目的:评估 10 年内个人肥胖相关并发症(ORCs)和多病症(≥ 1、≥ 2 和≥ 3 ORCs)的发病率,以及多病症相关的医疗费用:这项回顾性开放队列研究使用了英国的 "发现"(Discover)数据库,该数据库包含链接的一级和二级电子健康记录。根据体重指数(BMI;超重:25-2;肥胖 I 级:30-2;肥胖 II 级:35-2;肥胖 III 级:≥ 40 kg/m2)对成人进行分层。在整个研究期间(2004 年 1 月 1 日至 2019 年 12 月 31 日;指数日期为首次测量符合条件的 BMI 的日期),按基线年份评估结果:在 1 410 146 人中(超重:1 008 101 人;肥胖 I 级:278 782 人;肥胖 II 级:80 621 人;肥胖 III 级:42 642 人),ORC 患病率在连续的 BMI 组别中都较高,而且随着时间的推移,肥胖的患病率通常比超重的患病率高。在有器官功能障碍的多病人群中,体重指数越高、器官功能障碍越多,每人每年的医疗费用就越高。随着时间的推移,患有肥胖症和一种或多种口腔溃疡的患者,以及患有肥胖症和两种或多种口腔溃疡的患者的费用都会增加:结论:体重指数越高,ORC 的基线发病率越高,随着时间的推移,ORC 的发病率增加的幅度也越大,同时,多病人群的医疗费用也越高。为了减轻超重和肥胖对患者和医疗系统造成的负担,在制定有效的、有针对性的预防和管理护理路径时,应考虑 ORC 的存在、数量和类型。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Diabetes, Obesity & Metabolism
Diabetes, Obesity & Metabolism 医学-内分泌学与代谢
CiteScore
10.90
自引率
6.90%
发文量
319
审稿时长
3-8 weeks
期刊介绍: Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信